Online inquiry

IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3558MR)

This product GTTS-WQ3558MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MIF gene. The antibody can be applied in Inflammatory conditions research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002415.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4282
UniProt ID P14174
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3558MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12736MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ132MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ7955MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ15467MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ5716MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ12817MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ5634MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ13142MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04383119
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW